Androgens And Anabolic Steroids Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

Androgens and anabolic steroids are prescription medicines that mimic or supplement male sex hormones and are used for hypogonadism, breast cancer, anemia, delayed puberty, and muscle-wasting disorders. The global market is estimated at $61.97 billion in 2025 and is projected to grow at roughly 10.35% CAGR through the next decade. Demand is supported by both legitimate medical use and, in many jurisdictions, tightly regulated compounding or specialty pharmacy channels. North America accounts for the largest share, while Asia-Pacific is the fastest-expanding region.

• •Estimated 2025 market value: $61.97 billion with ~10.35% annual growth
• •Major therapeutic uses: hypogonadism, breast cancer, anemia, and muscle-wasting conditions
• •Largest region: North America; fastest-growing: Asia-Pacific

Rising diagnosis rates of testosterone deficiency and broader acceptance of hormone replacement therapy are the primary clinical drivers. An aging global male population, greater awareness of men's health issues, and expanding oncology indications for androgens also support volume growth. Improvements in drug delivery (long-acting injectables, transdermal gels, and oral formulations) and insurance coverage in developed markets further accelerate uptake.

• •Growing prevalence of hypogonadism and age-related testosterone decline
• •Expanding oncology use, particularly in breast cancer and supportive care
• •Innovation in long-acting injectables, transdermal, and oral androgen formulations

By indication, the market is led by hypogonadism, followed by breast cancer, anemia, and other uses such as delayed puberty and cachexia. By drug class, testosterone and its esters (enanthate, cypionate, propionate) dominate, alongside newer modified androgens and anabolic agents. Regionally, the United States contributes the single largest revenue pool, while China, India, and Southeast Asia show the steepest growth curves.

• •Leading indication: hypogonadism; other segments: breast cancer, anemia, supportive care
• •Leading drug class: testosterone and its esters, with growth in novel oral and modified androgens
• •Asia-Pacific is the fastest-growing regional market, driven by China and India

What are the recent trends and outlook?

Pipeline activity is focused on selective androgen receptor modulators (SARMs) and next-generation oral androgens aimed at improving safety and convenience. Digital men's health clinics and direct-to-patient telehealth platforms are expanding patient access to testosterone therapy in the U.S. and parts of Europe. Regulatory scrutiny on misuse remains high, but legitimate therapeutic demand is expected to keep the market on a strong double-digit growth trajectory through the early 2030s.

• •Pipeline emphasis on SARMs and improved oral and transdermal androgens
• •Telehealth and men's health platforms accelerating diagnosis and prescription rates
• •Tighter regulation of illicit use contrasts with continued expansion of legal prescription demand